3-甲基八氢吡咯并[1,2-A]吡嗪 | 1092297-90-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 3-甲基八氢吡咯并[1,2-A]吡嗪
• 英文名称: 3-Methyl-octahydropyrrolo[1,2-a]piperazine
• 英文别名: 3-methyl-1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine
• CAS: 1092297-90-9
• 化学式: C₈H₁₆N₂
• mdl: MFCD11108358
• 分子量: 140.23
• InChiKey: ZUILOGVUGKBLHW-UHFFFAOYSA-N

物化性质

• 沸点：
  203.2±8.0 °C(Predicted)
• 密度：
  1.00±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES
  申请人：Cheng Hengmiao

  公开号：US20090093463A1

  公开（公告）日：2009-04-09

  The present invention relates to compounds with the formula (I) or a pharmaceutically acceptable salt thereof: The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of 11-β-hsd-1, the method comprising administering to a mammal an effective amount of a compound of formula (I).

  本发明涉及公式(I)的化合物或其药学上可接受的盐：该发明还涉及包含公式(I)化合物的制药组合物，以及治疗通过调节11-β-hsd-1介导的疾病的方法，该方法包括向哺乳动物投与公式(I)化合物的有效量。
• [EN] TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF<br/>[FR] DÉRIVÉ DE TÉTRAHYDROISOQUINOLÉINE ET SON UTILISATION<br/>[ZH] 四氢异喹啉衍生物及其应用
  申请人：MEDSHINE DISCOVERY INC

  公开号：WO2022063094A1

  公开（公告）日：2022-03-31

  一系列四氢异喹啉衍生物及其晶型，具体公开了式(VII)所示化合物、其晶型及其药学上可接受的盐。
• NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES
  申请人：Pfizer, Inc.

  公开号：EP1812407A2

  公开（公告）日：2007-08-01
• [EN] NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES<br/>[FR] NOUVEAUX COMPOSES D'ADAMANTYL AMIDES SUBSTITUES OU NON
  申请人：PFIZER

  公开号：WO2006048750A2

  公开（公告）日：2006-05-11

  [EN] The present invention relates to compounds with the formula (I) or a pharmaceutically acceptable salt thereof: The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of 11-ß-hsd-1, the method comprising administering to a mammal an effective amount of a compound of formula (I).
  [FR] L'invention porte sur des composés de formule (I) et leurs sels pharmacocompatibles, ainsi que sur des procédés de traitement d'états médiés par la modulation du 11-ß-hsd-1, consistant à administrer à un mammifère une quantité efficace du composé de formule (1).
• [EN] GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE
  申请人：EXELIXIS INC

  公开号：WO2010091104A1

  公开（公告）日：2010-08-12

  The present invention comprises glucosylceramide synthase (GCS) inhibitors of structural formula (I), and pharmaceutically acceptable salts thereof, wherein R1, E, A, L, X1, Q, R4, R5, m and n, are as defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which GCS is a mediator or is implicated. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases in which GCS is a mediator or is implicated.